Celaid Therapeutics, Inc. will participate in the Cell & Gene Meeting on the Mesa 2026, taking place October 5–7, 2026, in Phoenix, Arizona, USA.
Yusuke Inoue, Board Director, COO & CFO, will represent Celaid and participate in partnering meetings with pharmaceutical and biotechnology companies, investors, and other industry stakeholders.
Celaid is advancing the development of HSC-based therapies and next-generation cell and gene therapy applications based on its proprietary ex vivo hematopoietic stem cell (HSC) expansion technology. At the meeting, we plan to discuss the development of our lead program, CLD-001, as well as potential research collaborations and strategic partnerships leveraging our HSC expansion platform.
Those interested in meeting with Celaid during the conference are welcome to contact us through the Meeting on the Mesa partnering system or via our website.
